Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections

doi:10.12998/wjcc.v10.i3.856

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 3

This Article

(235)

(236)

(0)

(3)

(6508)

(9)

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Study

World J Clin Cases. Jan 21, 2022; 10(3): 856-869
Published online Jan 21, 2022. doi: 10.12998/wjcc.v10.i3.856

Table 3 Clinicopathological data between the three immune subtypes

Variable		Immune^high	Immune^mod	Immune^low
HBV DNA	Positive	30	30	5
	Negative	38	54	16
	Not mentioned	15	10	6
MaVI	Yes	8	10	3
MaVI	No	75	84	24
MVI	Yes	34	58	18
MVI	No	49	36	9
Tumor number	Single	60	78	18
Tumor number	Multiple (≥ 2)	23	16	9
Largest tumor diameter	≤ 10	80	85	24
Largest tumor diameter	> 10	3	9	3
Capsule	Yes	48	53	16
Capsule	No	35	41	11
Neutrophils	Yes	19	19	1
Neutrophils	No	64	75	26
Tertiary lymphoid structures	Yes	7	3	0
Tertiary lymphoid structures	No	76	91	27
Differentiation	Moderately differentiated	40	50	17
Differentiation	Poorly differentiated	43	44	10
Histological subtype	Microtrabecular/pseudoglandular	39	40	13
	Macrotrabecular	38	52	14
	Compact	3	2	0
	Lymphoepithelioma-like	3	0	0
PD-L1 expression	Tumor cells	24	44	12
PD-L1 expression	TILs	79	94	26
Recurrence	Yes	9	24	9
Recurrence	No	74	70	18

MaVI: Macrovascular invasion; MVI: Microvascular invasion; PD-L1: Programmed cell death-ligand 1; TIL: Tumor infiltrating lymphocyte; HBV: Hepatitis B virus.

Full Size Table

Citation: Du M, Cai YM, Yin YL, Xiao L, Ji Y. Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections. World J Clin Cases 2022; 10(3): 856-869
URL: https://www.wjgnet.com/2307-8960/full/v10/i3/856.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i3.856

Du M, Cai YM, Yin YL, Xiao L, Ji Y. Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections. World J Clin Cases 2022; 10(3): 856-869 [PMID: 35127901 DOI: 10.12998/wjcc.v10.i3.856]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.